DBV Technologies Announces Financial Calendar 2017
Jan 09, 2017 06:40 am UTC| Business
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), today announced its 2017 financial calendar[1] : February 20, 2017 - cash position December 31, 2016March 15, 2017 - full-year 2016...
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb
Jan 09, 2017 06:06 am UTC| Business
Innate Pharma receives $15 million milestone payment from Bristol-Myers Squibb for continued exploration of lirilumab in combination with Opdivo Marseille, January 9, 2017 Innate Pharma SA (the "Company" -...
How speeding up payments to small businesses creates jobs
Jan 09, 2017 06:06 am UTC| Insights & Views Economy Business
Operating a small business, the backbone of the U.S. economy, has always been tough. But theyve also been disproportionately hurt by the Great Recession, losing 40 percent more jobs than the rest of the private sector...
Takeda notifies 4.48% shareholding in TiGenix
Jan 09, 2017 06:05 am UTC| Business
TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") publishes today a transparency notification pursuant to Article14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose...
MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO
Jan 09, 2017 06:03 am UTC| Business
On track to meet full-year earnings guidance based on strong ConfirmMDx growthJean-Marc Roelandt appointed Chief Financial Officer IRVINE, CA, and HERSTAL, BELGIUM - January 9, 2017 - MDxHealth SA (Euronext:...
U.S. Condom Market will reach USD 1,680.22 Million by 2022: Zion Market Research
Jan 09, 2017 06:02 am UTC| Business
Sarasota, FL, Jan. 09, 2017 -- Zion Market Research has published a new report titled “Condom Market by Gender (Male and Female), Distribution Channel (Commercial Outlets, Non-commercial Outlets, and Non-traditional...
Jan 09, 2017 06:00 am UTC| Business
MONT-SAINT-GUIBERT, Belgium, Jan. 09, 2017 -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell-based therapies, announced today that the...